Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholester…
Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak Novartis to join collaborative R&D efforts with the Bill & Melinda Gates Foundation, W…
Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak Novartis to join collaborative R&D efforts with the Bill & Melinda Gates Foundation, W…
October 01, 2021Enabling our associates to work safely on our sitesAs a leading healthcare company, Novartis is playing an important part by supporting vaccination to help overcome the pandemic. The safety of all associates, our customers, business par…
This is the story of how 3 Novartis colleagues took a career decision to improve health in lower income countries.This series provides a glimpse into their experiences, challenges and the reward of seeing lives changed. …
At Novartis, our people are exceptional. They do amazing work every day to reimagine medicine and improve the lives of patients all over the world. We want to build an inclusive environment that values these unique and curious minds, where everyone is …
At Novartis, our people are exceptional. They do amazing work every day to reimagine medicine and improve the lives of patients all over the world. We want to build an inclusive environment that values these unique and curious minds, where everyone is …
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million. The PAMAfrica consortium brings together a global medicines company, a not-for-profit product de…
Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long antitrust investigation into the U.S. generic drug industry. …
March 11, 2020Patient safety is at the heart of everything we do. Whenever adverse events are reported, we take them seriously and investigate them thoroughly. As previously shared, our global safety organization is conducting a comprehensive review of…